Sure, each situation needs to be assessed on its own merits but, in general, P2 results haven't been shown to be all that predictive of P3 success. The reality is that since 2007 the Phase III failure rate for new drugs has been around 50%. The # 1 reason (66%) is due to lack of efficacy. I'm fairly certain that these drugs all showed positive efficacy in their P2 trials as well ;)
News 
Market Data 
Discover 
